Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes
Status:
Withdrawn
Trial end date:
2027-05-28
Target enrollment:
Participant gender:
Summary
This study compares the medicines semaglutide with empagliflozin or metformin in people with
newly diagnosed type 2 diabetes. This study will look mainly at how well participant's blood
sugar and body weight are controlled when they are taking the study medicines. Participants
will either get semaglutide tablets, empagliflozin tablets or metformin tablets. Which
treatment participants will get is decided by chance. Currently, doses of 3 milligram (mg), 7
mg and 14 mg semaglutide tablets (Rybelsus) can be prescribed in some countries. 25 mg and 50
mg semaglutide tablets are new doses. 10 mg and 25 mg empagliflozin tablets (Jardiance) can
be prescribed in some countries. 500 mg metformin tablets (STADA) can be prescribed in some
countries. Participants will get 1 to 4 tablets per day for 104 weeks. The study will last
for about 2 years and 7 weeks (111 weeks). Participants should not have been treated for
weight management 90 days before screening or never been treated with any medicine for type 2
diabetes (except diabetes during pregnancy) before screening. Women cannot take part if
pregnant, breast-feeding or plan to get pregnant during the study period.